Back to Journals » Drug Design, Development and Therapy » Volume 3

Review

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

       
Total article views   HTML views PDF downloads Totals
8,909 Dovepress* 8,909+ 3,063 11,972
Totals 8,909 3,063 11,972
*Since 27 March 2009
+Since July 2016

View citations on Google Scholar